...
首页> 外文期刊>The journal of immunology >Mixed Xenogeneic Chimerism Induces Donor-Specific Humoral and Cellular Immune Tolerance for Cardiac Xenografts
【24h】

Mixed Xenogeneic Chimerism Induces Donor-Specific Humoral and Cellular Immune Tolerance for Cardiac Xenografts

机译:混合异种嵌合体诱导心脏异种移植的供体特异性体液和细胞免疫耐受。

获取原文

摘要

Xenotransplantation has been suggested as a potential solution to the critical shortage of donor organs. However, success has been limited by the vigorous rejection response elicited against solid organs transplanted across species barriers. Mixed xenogeneic bone marrow chimeras resulting from the transplantation of a mixture of host and donor marrow (B10 mouse + F344 rat → B10 mouse) results in donor-specific cross-species transplantation tolerance for subsequent nonvascularized skin and islet grafts. Furthermore, compared with fully xenogeneic chimeras (rat → mouse), mixed xenogeneic chimeras exhibit superior immunocompetence for infectious agents in vivo and in vitro, suggesting that the immune system is intact. The ability to establish long-term humoral and cellular tolerance for primarily vascularized xenografts in vivo, in the setting of both recipient and donor Ig and effector cell production, has not previously been characterized. Mixed xenogeneic chimeras exhibit donor-specific humoral tolerance as evident by the absence of anti-donor Ab and Ab-dependent donor-specific cytotoxicity in vitro and intravascular IgM deposition within donor-strain (F344) cardiac xenografts in vivo. F344 cardiac xenografts are accepted (median ≥180 days) without clinical or histologic evidence of rejection, suggesting cellular tolerance. In contrast, MHC-disparate third-party mouse (B10.BR) and rat (ACI or WF) grafts are rejected (median of 23 and 41 days, respectively) in association with extensive mononuclear cell infiltration and vascular deposits of mouse IgM. These results demonstrate that mixed xenogeneic chimerism establishes donor-specific humoral and cellular tolerance and permits the successful transplantation of even primarily vascularized xenografts in the setting of intact Ab production.
机译:已经提出异种移植可以作为解决供体器官严重短缺的潜在方法。但是,成功的成功受到了针对跨物种壁垒移植的实体器官的强烈排斥反应的限制。宿主和供体骨髓混合物的移植(B10小鼠+ F344大鼠→B10小鼠)的混合异种骨髓嵌合体导致供体特异性跨物种移植耐受随后的非血管化皮肤和胰岛移植。此外,与完全异种嵌合体(大鼠→小鼠)相比,混合异种嵌合体在体内和体外均表现出优异的针对传染原的免疫能力,这表明免疫系统是完整的。在受体Ig和供体Ig以及效应细胞产生的背景下,对于体内主要血管化的异种移植物建立长期体液和细胞耐受性的能力先前未被表征。混合异种嵌合体表现出供体特异性的体液耐受性,这在体外不存在抗供体Ab和Ab依赖的供体特异性细胞毒性以及体内供体株(F344)心脏异种移植物中血管内IgM沉积的情况下很明显。 F344心脏异种移植被接受(中位数≥180天),没有临床或组织学排斥反应,提示细胞耐受。相反,与MHC不同的第三方小鼠(B10.BR)和大鼠(ACI或WF)移植物被排斥(分别为中位数23天和41天),这与小鼠IgM的广泛单核细胞浸润和血管沉积有关。这些结果表明,混合的异种嵌合体建立了供体特异性的体液和细胞耐受性,并允许在完整的Ab生产中成功移植甚至主要是血管化的异种移植物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号